m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00299)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
JAK2
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | Raw 264.7 cell line | Mus musculus |
Treatment: METTL3 knockout Raw 264.7 cells
Control: Wild type Raw 264.7 cells
|
GSE162248 | |
Regulation |
|
logFC: -7.87E-01 p-value: 4.26E-20 |
More Results | Click to View More RNA-seq Results | |
Representative RIP-seq result supporting the interaction between JAK2 and the regulator | ||
Cell Line | MDA-MB-231 | Homo sapiens |
Regulation | logFC: 7.70E+00 | GSE60213 |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | METTL3 knockdown prevented Atherosclerosis progression by inhibiting Tyrosine-protein kinase JAK2 (JAK2)/STAT3 pathway via IGF2BP1. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Atherosclerosis | ICD-11: BD40.Z | ||
Pathway Response | JAK-STAT signaling pathway | hsa04630 | ||
Cell Process | Cell proliferation and migration | |||
In-vitro Model | HUVEC-C | Normal | Homo sapiens | CVCL_2959 |
In-vivo Model | The adeno-associated viruses (AAV) that could silence METTL3 (sh-METTL3) and the negative control adeno-associated viruses (sh-NC) were obtained from WZ Biosciences Inc. (Jinan, China). APOE-/- mice were randomly divided into AS + sh-NC and AS + sh-METTL3 groups. Each group contains five mice. Mice were fed with the standard diet for 1 week to acclimatize. After 1 week of acclimation, mice were challenged with a high-fat and high-cholesterol feed H10540 (Beijing HFK BIOSCIENCE Co., Ltd., Beijing, China). The formula of the H10540 feed was shown in Supplementary File S1. After 8 weeks of HFD feeding, sh-NC or sh-METTL3 adeno-associated virus serotype 9 (AAV9, 1012 viral genome copies per mouse) were respectively delivered into mice in AS + sh-NC or AS + sh-METTL3 group through tail vein injection. At 14 weeks after HDF feeding, mice fasted overnight. | |||
Fat mass and obesity-associated protein (FTO) [ERASER]
Representative RNA-seq result indicating the expression of this target gene regulated by FTO | ||
Cell Line | 253J cell line | Homo sapiens |
Treatment: siFTO 253J cells
Control: 253J cells
|
GSE150239 | |
Regulation |
|
logFC: 9.68E-01 p-value: 1.29E-02 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | FTO inhibits adipocytes apoptosis via reducing m6A epigenetic modification-mediated UPRmt.UPRmt-induced increase in PKR and eIF2-alpha phosphorylation, and ATF5-mediated upregulation of BAX expression promoted apoptosis. Furthermore, adipocytes apoptosis is inhibited by FTO-activated Tyrosine-protein kinase JAK2 (JAK2)/STAT3 signaling pathway | |||
Pathway Response | Adipocytokine signaling pathway | hsa04920 | ||
JAK-STAT signaling pathway | hsa04630 | |||
Cell Process | Mitochondria-dependent apoptosis | |||
Cell apoptosis | ||||
In-vitro Model | 3T3-L1 | Normal | Mus musculus | CVCL_0123 |
In-vivo Model | Mice were provided adlibitum with water and a standard laboratory chow diet. The animal room was held a standard temperature, humidity and illumination. After intraperitoneal injection of FTO overexpression vector and NR to mice for 7 days, inguinal white adipose tissue (iWAT) were collected from mice. | |||
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) [READER]
Representative RNA-seq result indicating the expression of this target gene regulated by IGF2BP1 | ||
Cell Line | HepG2 cell line | Homo sapiens |
Treatment: siIGF2BP1 HepG2 cells
Control: siControl HepG2 cells
|
GSE161086 | |
Regulation |
|
logFC: -1.30E+00 p-value: 1.73E-03 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | METTL3 knockdown prevented Atherosclerosis progression by inhibiting Tyrosine-protein kinase JAK2 (JAK2)/STAT3 pathway via IGF2BP1. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Atherosclerosis | ICD-11: BD40.Z | ||
Pathway Response | JAK-STAT signaling pathway | hsa04630 | ||
Cell Process | Cell proliferation and migration | |||
In-vitro Model | HUVEC-C | Normal | Homo sapiens | CVCL_2959 |
In-vivo Model | The adeno-associated viruses (AAV) that could silence METTL3 (sh-METTL3) and the negative control adeno-associated viruses (sh-NC) were obtained from WZ Biosciences Inc. (Jinan, China). APOE-/- mice were randomly divided into AS + sh-NC and AS + sh-METTL3 groups. Each group contains five mice. Mice were fed with the standard diet for 1 week to acclimatize. After 1 week of acclimation, mice were challenged with a high-fat and high-cholesterol feed H10540 (Beijing HFK BIOSCIENCE Co., Ltd., Beijing, China). The formula of the H10540 feed was shown in Supplementary File S1. After 8 weeks of HFD feeding, sh-NC or sh-METTL3 adeno-associated virus serotype 9 (AAV9, 1012 viral genome copies per mouse) were respectively delivered into mice in AS + sh-NC or AS + sh-METTL3 group through tail vein injection. At 14 weeks after HDF feeding, mice fasted overnight. | |||
RNA demethylase ALKBH5 (ALKBH5) [ERASER]
Representative RNA-seq result indicating the expression of this target gene regulated by ALKBH5 | ||
Cell Line | NOMO-1 cell line | Homo sapiens |
Treatment: shALKBH5 NOMO-1 cells
Control: shNS NOMO-1 cells
|
GSE144968 | |
Regulation |
|
logFC: 1.17E+00 p-value: 2.74E-05 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [3] | |||
Response Summary | The ALKBH5-HOXA10 loop jointly activates the JAK2/STAT3 signaling pathway by mediating Tyrosine-protein kinase JAK2 (JAK2) m6A demethylation, promoting epithelial ovarian cancer resistance to cisplatin. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Malignant mixed epithelial mesenchymal tumour of ovary | ICD-11: 2B5D.0 | ||
Responsed Drug | Cisplatin | Approved | ||
Pathway Response | JAK-STAT signaling pathway | hsa04630 | ||
In-vitro Model | HO8910-DDP (HO8910 underwent continuous stepwise exposure to increasing concentrations of cisplatin to create the cisplatin-resistant cell lines HO8910-DDP) | |||
HO-8910 | Endocervical adenocarcinoma | Homo sapiens | CVCL_6868 | |
A2780-DDP (A2780 underwent continuous stepwise exposure to increasing concentrations of cisplatin to create the cisplatin-resistant cell line) | ||||
A2780 | Ovarian endometrioid adenocarcinoma | Homo sapiens | CVCL_0134 | |
In-vivo Model | About 5× 106 cells were injected subcutaneously into the axilla of the female athymic BALB/C nude mice (4 week-old, 18-20?g). When the average tumor size reached approximately 100mm3 (after 1 week), mice were then randomized into two groups and treated with cisplatin (5 mg/kg) or normal saline (NS) weekly. | |||
Malignant mixed epithelial mesenchymal tumour [ICD-11: 2B5D]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [3] | |||
Response Summary | The ALKBH5-HOXA10 loop jointly activates the JAK2/STAT3 signaling pathway by mediating Tyrosine-protein kinase JAK2 (JAK2) m6A demethylation, promoting epithelial ovarian cancer resistance to cisplatin. | |||
Responsed Disease | Malignant mixed epithelial mesenchymal tumour of ovary [ICD-11: 2B5D.0] | |||
Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
Target Regulation | Up regulation | |||
Responsed Drug | Cisplatin | Approved | ||
Pathway Response | JAK-STAT signaling pathway | hsa04630 | ||
In-vitro Model | HO8910-DDP (HO8910 underwent continuous stepwise exposure to increasing concentrations of cisplatin to create the cisplatin-resistant cell lines HO8910-DDP) | |||
HO-8910 | Endocervical adenocarcinoma | Homo sapiens | CVCL_6868 | |
A2780-DDP (A2780 underwent continuous stepwise exposure to increasing concentrations of cisplatin to create the cisplatin-resistant cell line) | ||||
A2780 | Ovarian endometrioid adenocarcinoma | Homo sapiens | CVCL_0134 | |
In-vivo Model | About 5× 106 cells were injected subcutaneously into the axilla of the female athymic BALB/C nude mice (4 week-old, 18-20?g). When the average tumor size reached approximately 100mm3 (after 1 week), mice were then randomized into two groups and treated with cisplatin (5 mg/kg) or normal saline (NS) weekly. | |||
Atherosclerosis [ICD-11: BD40]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | METTL3 knockdown prevented Atherosclerosis progression by inhibiting Tyrosine-protein kinase JAK2 (JAK2)/STAT3 pathway via IGF2BP1. | |||
Responsed Disease | Atherosclerosis [ICD-11: BD40.Z] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | JAK-STAT signaling pathway | hsa04630 | ||
Cell Process | Cell proliferation and migration | |||
In-vitro Model | HUVEC-C | Normal | Homo sapiens | CVCL_2959 |
In-vivo Model | The adeno-associated viruses (AAV) that could silence METTL3 (sh-METTL3) and the negative control adeno-associated viruses (sh-NC) were obtained from WZ Biosciences Inc. (Jinan, China). APOE-/- mice were randomly divided into AS + sh-NC and AS + sh-METTL3 groups. Each group contains five mice. Mice were fed with the standard diet for 1 week to acclimatize. After 1 week of acclimation, mice were challenged with a high-fat and high-cholesterol feed H10540 (Beijing HFK BIOSCIENCE Co., Ltd., Beijing, China). The formula of the H10540 feed was shown in Supplementary File S1. After 8 weeks of HFD feeding, sh-NC or sh-METTL3 adeno-associated virus serotype 9 (AAV9, 1012 viral genome copies per mouse) were respectively delivered into mice in AS + sh-NC or AS + sh-METTL3 group through tail vein injection. At 14 weeks after HDF feeding, mice fasted overnight. | |||
Experiment 2 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | METTL3 knockdown prevented Atherosclerosis progression by inhibiting Tyrosine-protein kinase JAK2 (JAK2)/STAT3 pathway via IGF2BP1. | |||
Responsed Disease | Atherosclerosis [ICD-11: BD40.Z] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | JAK-STAT signaling pathway | hsa04630 | ||
Cell Process | Cell proliferation and migration | |||
In-vitro Model | HUVEC-C | Normal | Homo sapiens | CVCL_2959 |
In-vivo Model | The adeno-associated viruses (AAV) that could silence METTL3 (sh-METTL3) and the negative control adeno-associated viruses (sh-NC) were obtained from WZ Biosciences Inc. (Jinan, China). APOE-/- mice were randomly divided into AS + sh-NC and AS + sh-METTL3 groups. Each group contains five mice. Mice were fed with the standard diet for 1 week to acclimatize. After 1 week of acclimation, mice were challenged with a high-fat and high-cholesterol feed H10540 (Beijing HFK BIOSCIENCE Co., Ltd., Beijing, China). The formula of the H10540 feed was shown in Supplementary File S1. After 8 weeks of HFD feeding, sh-NC or sh-METTL3 adeno-associated virus serotype 9 (AAV9, 1012 viral genome copies per mouse) were respectively delivered into mice in AS + sh-NC or AS + sh-METTL3 group through tail vein injection. At 14 weeks after HDF feeding, mice fasted overnight. | |||
Cisplatin
[Approved]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [3] | |||
Response Summary | The ALKBH5-HOXA10 loop jointly activates the JAK2/STAT3 signaling pathway by mediating Tyrosine-protein kinase JAK2 (JAK2) m6A demethylation, promoting epithelial ovarian cancer resistance to cisplatin. | |||
Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Malignant mixed epithelial mesenchymal tumour of ovary | ICD-11: 2B5D.0 | ||
Pathway Response | JAK-STAT signaling pathway | hsa04630 | ||
In-vitro Model | HO8910-DDP (HO8910 underwent continuous stepwise exposure to increasing concentrations of cisplatin to create the cisplatin-resistant cell lines HO8910-DDP) | |||
HO-8910 | Endocervical adenocarcinoma | Homo sapiens | CVCL_6868 | |
A2780-DDP (A2780 underwent continuous stepwise exposure to increasing concentrations of cisplatin to create the cisplatin-resistant cell line) | ||||
A2780 | Ovarian endometrioid adenocarcinoma | Homo sapiens | CVCL_0134 | |
In-vivo Model | About 5× 106 cells were injected subcutaneously into the axilla of the female athymic BALB/C nude mice (4 week-old, 18-20?g). When the average tumor size reached approximately 100mm3 (after 1 week), mice were then randomized into two groups and treated with cisplatin (5 mg/kg) or normal saline (NS) weekly. | |||
References